How TB-500 Affects ALT

TB-500 is the synthetic version of thymosin beta-4 (Tβ4), a naturally occurring actin-binding peptide involved in cell migration, angiogenesis and tissue repair. It is important to separate the acute lab picture from the chronic biological concern, because they point in different directions.

Acute effect on ALT (what a blood test sees):

• There is no published human trial measuring ALT, AST or GGT response to TB-500 at any dose or route.
• TB-500 is not a direct hepatotoxin. It is not 17-alpha-alkylated and has no known mechanism for causing the acute hepatocellular injury that raises ALT.
• So on a standard panel, ALT is expected to stay at baseline. Any change you see is far more likely to come from something else in your stack (orals, training, alcohol).

Chronic liver signal (why TB-500 is not "hepatoprotective"): This is where TB-500 diverges sharply from BPC-157. BPC-157 is protective against liver injury in rodents. Tβ4 in the liver looks the opposite:

• Targeted deletion of thymosin beta-4 from hepatic stellate cells reduced liver fibrosis in a transgenic mouse model, which means endogenous Tβ4 is pro-fibrotic in the liver by driving stellate cell activation (Kim et al., 2023, PMID 37371128). Stellate cell activation is the central event in liver fibrosis.
• The Tβ4 gene (TMSB4X) promotes proliferation, migration and invasion of hepatocellular carcinoma cells (Tang et al., 2024, PMID 39556271), consistent with the broader pattern of Tβ4 overexpression across solid tumours.

None of this shows up as an ALT change in the short term. The point is that injecting supraphysiological Tβ4 has a theoretical pro-fibrotic and pro-tumour signal in liver tissue, which is a monitoring reason to keep an eye on liver health over time, not evidence of acute toxicity.

Healthy users on TB-500 alone:

• ALT expected to stay at baseline. No published human data shows a change.
• Same for AST, GGT and bilirubin.

TB-500 stacked with hepatotoxic orals (dianabol, anadrol, halotestin, superdrol):

• Any ALT elevation you see is driven by the oral, not the TB-500.
• TB-500 will not "protect" your liver from that damage; the hepatoprotective claim belongs to BPC-157's rodent data, and even that is unproven in humans.

Over months to years:

• No lab marker reliably captures the theoretical fibrosis/tumour concern early. This is a reason for periodic liver imaging or specialist review if using long term, not something a single ALT reading rules out.

Baseline: A standard liver panel (ALT, AST, GGT, bilirubin) before starting, mostly so you can attribute any later change to the right cause.

During use:

• Recheck the liver panel on your normal cycle schedule if TB-500 is stacked with oral AAS, since the orals are the real ALT driver.
• Do not expect TB-500 itself to move ALT. A rising ALT on a TB-500-plus-orals stack is an oral problem.

Long-term / repeated use:

• The pro-fibrotic and oncological signals are chronic and not captured by ALT. If you use TB-500 in long or repeated blocks, factor in periodic liver imaging and a frank conversation with a doctor, especially given any family history of liver disease or cancer.

• Do not use TB-500 as liver protection. That is a BPC-157 talking point, and it is unproven even there. TB-500's own liver signal points the wrong way.
• If your ALT rises on a stack that includes TB-500, look at your orals, alcohol and training first. TB-500 is almost never the cause of an acute ALT bump.
• Keep TB-500 blocks time-limited rather than continuous, which is sensible risk management given the pro-angiogenic and pro-fibrotic signals.
• Anyone with a personal or family history of liver disease or cancer should be especially cautious, since the theoretical concern is exactly in that territory.